Renaud Vaillant

Based in Paris and in the USA, TheraVectys is an immunotherapy company spun off from the Institut Pasteur created in 2005 by Dr. Pierre Charneau. TheraVectys is pioneering the application of novel lentiviral vector technology to address most of unmet and critical medical needs. By creating the only Joint-Laboratory between a private company and the Institut Pasteur in Paris, TheraVectys develops an extensive pipeline of vaccine candidates to drive the widespread treatment and prevention of cancer and infectious diseases. Leveraging our proprietary technology platform, and the extensive virology expertise of the Institut Pasteur, TheraVectys provides a robust and highly effective transfection mechanism to elicit a potent and targeted immune response previously unseen.

At Alaya.bio, were developing a revolutionary targeting polymeric nanoparticle that enhances the transduction efficiency of quiescent cells such as T-cells, NK-cells, and stem cells. Our platform eliminates the need for activation factors or cytokines, resulting in reduced exhaustion of transduced cells while preserving their naive and memory phenotypes, leading to better clinical outcomes.

Ixaka (formerly Rexgenero) is a private UK-based cell and gene therapy company with operations in the UK, Spain and France. The company is focused on the natural power of the body to cure disease. Our proprietary technologies enhance the inherent therapeutic power of cells by targeting curative cells to the site of disease and by directly modifying cells within the body to improve their therapeutic action. Ixaka’s technologies – concentrated multi-cell therapies and targeted nano-particles – demonstrate potential for the treatment of a broad range of serious diseases across oncology, cardiovascular, neurological and ocular diseases, and genetic disorders. Ixaka has offices in London, UK, with R&D and manufacturing operations in Seville, Spain and Paris, France, and additional manufacturing capability in Frankfurt, Germany.

aratinga.bio is a preclinical stage company developing novel immunotherapies to treat cancer. To address unmet medical needs, aratinga.bio is developing its proprietary platform effective against both hematological cancers and solid tumors regardless of the type of previous treatments patients have experienced. The use of human T cells as therapeutics and the administration of anti-checkpoints are revolutionizing the way cancer is treated. We believe investments in research capabilities including access to state-of-the-art gene transfer and nucleotide-based technologies, will help accelerate the development of new and better options for immune-oncology therapeutics

Mooncard, the reinvented expense management solution, covers everything from payment to accounting. It offers a platform, cards, and a mobile app to optimize operational team efficiency while giving control to finance teams. Mooncard provides: - **A platform for automatic expense management and accounting:** Customize and set rules, instant visibility by person or team, and simplified accounting integration. - **Physical or virtual payment cards for all needs:** Customized settings according to expense policies and real-time budget tracking. - **Automated expense reports:** Automated receipt retrieval system, personalized approval workflows, one-click reimbursement for employees, and 100% VAT recovery. Present in France, Germany, Austria, Belgium, Italy, Spain and the Netherlands, Mooncard has already won over more than 6 000 companies as well as the French State.